Composition for the prevention or treatment of atopic dermatitis comprising an inhibitor of skin-specific T cells as an active ingredient

Pharmaceutical composition for treating atopic dermatitis using quinazolinone derivatives to inhibit skin-specific T cells

This technology features a pharmaceutical composition for preventing and treating atopic dermatitis, and a cosmetic composition for alleviating and improving symptoms, both containing a fluorinated, ethyl-substituted quinazolinone compound or its acceptable salts as an active ingredient. The compound works by reducing the number and activity of skin-resident, skin-specific T cells.

Atopic dermatitis has traditionally been treated with topical steroids or immunosuppressants, but these often provide only temporary relief, are unsuitable for long-term use, and carry risks of systemic absorption side effects in infants and the elderly. Topical calcineurin inhibitors, developed as steroid alternatives, have high molecular weights that limit absorption in thickened lesions and have been linked to side effects like lichenification. Furthermore, most treatments have focused on systemic, blood-based approaches despite the disease being localized to skin tissue, making it difficult to effectively control the lesions themselves.

Instead of suppressing the systemic immune system, this technology selectively inhibits skin-specific T cells, reducing serum total IgE and eosinophil counts while improving skin lesions. Formulated for topical application that penetrates the stratum corneum, it allows for targeted immune control at the lesion site with minimal toxicity to healthy skin, making it suitable for long-term use in chronic conditions. It can be applied to transdermal delivery systems, atopic relief cosmetics, and therapeutic screening, enabling the development of skin-tailored immunomodulatory products without systemic side effects.

‍

‍

Key Features:

• Pharmaceutical composition for treating atopic dermatitis comprising a quinazolinone compound where X is F and R1 is C2 alkyl, or a pharmaceutically acceptable salt thereof, as an active ingredient
• Cosmetic composition for alleviating or improving atopic dermatitis comprising the same compound or a cosmetically acceptable salt thereof as an active ingredient
• Composition that acts to reduce the number or activity of skin-specific T cells present in skin tissue
• Composition for preventing or treating atopic dermatitis formulated as a transdermal delivery agent or topical skin application for use on lesion sites

‍

This invention was developed with support from the Ministry of Science and ICT for the development of skin-specific atopic dermatitis therapeutics targeting the PI3K/Akt signaling pathway.

‍